Second Prolibra(R) Study Shows Improved Body Composition by Targeting Fat Loss

MONROE, Wis., June 6 /PRNewswire/ — A new report by Glanbia Nutritionals confirms that Prolibra has been clinically proven to have a significant impact on fat loss and muscle mass retention. In the 12-week double-blind, placebo- controlled study, researchers found that adults consuming Prolibra lost 82% more fat than the placebo group, and retained twice as much lean muscle mass.

“We are happy to announce that the results of this second clinical study confirm and significantly strengthen the results of our first human clinical trial, proving that Prolibra is a safe, natural solution to healthy, long-term weight management,” said Dr. Eric Bastian, Vice President of Research and Development at Glanbia Nutritionals. “Prolibra is a patent-pending ingredient with GRAS status, which we’ve successfully formulated into a variety of food, beverage and supplement systems.”

Retention of lean muscle mass during dieting contributes to a healthy Basal Metabolic Rate (BMR). This can eliminate the frustrating effects of yo- yo dieting, a common occurrence with traditional diets which fail to address lean muscle mass maintenance. The synergistic effect of Prolibra’s unique components, including proprietary whey peptides, contributed to significant fat loss while preserving lean muscle mass.

The 12-week study was designed to measure the effect of Prolibra on body composition. A group of adults (BMI 30 to 42 kg/m2) was randomly divided into a treatment group and a placebo group. The groups were assigned to consume Prolibra or a placebo, twice a day. Both groups were instructed to reduce their caloric intake by 500 calories per day and received dietary counseling. Fifty-nine individuals completed the study.

The results of the study provide the basis for substantiated claims which can be used to support finished products containing Prolibra. According to Sharon Rokosh, Business Development Manager at Glanbia Nutritionals, “We’ve had the study and resulting claims substantiated by legal review, so our customers can be confident not only in the benefits of Prolibra, but also in how to state them.”

For more information on Prolibra research, please send an e-mail to [email protected] or contact Sharon Rokosh at (608) 329-2800.

Glanbia Nutritionals is a division of Glanbia plc, a leading international food company headquartered in Kilkenny, Ireland. Glanbia plc is one of Europe’s leading dairy companies, and one of the world’s largest cheese manufacturers.

First Call Analyst:
FCMN Contact:

Source: Glanbia Nutritionals